Skip to main content
Log in

Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To investigate the effect of vitamin E-TPGS, d-α-tocopheryl polyethylene glycol 1000 succinate, on the solubility and permeability of amprenavir, a potent HIV protease inhibitor.

Methods. The aqueous solubility of amprenavir was measured as a function of vitamin E-TPGS concentration. Directional transport through Caco-2 cell monolayers was determined in the presence and absence of vitamin E-TPGS and P-glycoprotein inhibitors. Absorption flux was estimated from Caco-2 cell permeability and aqueous solubility.

Results. The solubility of amprenavir in a pH 7 buffer at 37°C was 0.036 ± 0.007 mg/mL. The solubility linearly increased with increasing vitamin E-TPGS concentration (above 0.2 mg/mL). Polarized transport was demonstrated in the basolateral to apical direction, exceeding apical to basolateral transport by a factor of 6. The active efflux system was inhibited by vitamin E-TPGS and known P-glycoprotein inhibitors verapamil and GF120918.

Conclusions. The solubility of amprenavir was improved in the presence of vitamin E-TPGS through micelle solubilization. Vitamin E-TPGS inhibits the efflux system and enhances the permeability of amprenavir. Overall, vitamin E-TPGS enhanced the absorption flux of amprenavir by increasing its solubility and permeability. The enhancement is essential to the development of the novel soft gelatin capsule formulation of amprenavir for use in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. J. C. Adkins and D. Faulds. Amprenavir. Drugs 55:837-842 (1998).

    Google Scholar 

  2. A. K. Roy and L. G. Tillman. Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble vitamin E compound such as vitamin E-TPGS. WO 97/35587, 1997.

  3. Pharmaceutical ingredients: Vitamin E TPGS properties and applications. Eastman Chemical Co. 1996.

  4. R. J. Sokol, N. Butler-Simon, C. Conner, J. E. Heubi, F. R. Sinatra, F. J. Suchy, M. B. Heyman, J. Perrault, R. J. Rothbaum, J. Levy, S. T. Iannaccone, B. L. Shneider, T. K. Koch, and M. R. Narkewicz. Multicenter trial of d-α-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology 104: 1727-1735 (1993).

    Google Scholar 

  5. R. J. Sokol, K. E. Johnson, F. M. Karrer, M. R. Narkewicz, D. Smith, and I. Kam. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitmain E. Lancet 338:212-215 (1991).

    Google Scholar 

  6. T. Chang, L. Z. Benet, and M. F. Hebert. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in health volunteers. Clin. Pharmacol. Ther. 59:297-303 (1996).

    Google Scholar 

  7. M. F. Hebert. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Del. Rev. 27:201-214 (1997).

    Google Scholar 

  8. R. N. Kim, M. F. Fromm, C. Wandel, Brenda Leake, A. J. J. Wood, D. M. Roden, and G. W. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-protease inhibitors. J. Clin. Invest. 101:289-294 (1998).

    Google Scholar 

  9. J. Alsenz, H. Steffen, and R. Alex. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15:423-428 (1998).

    Google Scholar 

  10. A. E. Kim, J. M. Dintaman, D. S. Waddell, and J. S. Silverman. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286:1439-1445 (1998).

    Google Scholar 

  11. M. M. Nerurkar, P. S. Burton, and R. T. Borchardt. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:528-534 (1996).

    Google Scholar 

  12. M. M. Nerurkar, N. F. H. Ho, P. S. Burton, T. J. Vidmar, and R. T. Borchardt. Mechanistic roles of neural surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:813-821 (1997).

    Google Scholar 

  13. Y.-L. Lo, C.-Y. Shu, and J.-D. Huang. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line. Anticancer Res. 18:3005-3010 (1998).

    Google Scholar 

  14. G. Ismailos, C. Reppas, and P. Macheras. Enhancement of cyclosporin A solubility by d-alphatocopheryl-polyethylence-glycol-1000 succinate (TPGS). Eur. J. Pharm. Sci. 1:269-271 (1994).

    Google Scholar 

  15. G. Zografi, H. Schott, and J. Swarbrick. Disperse systems. Surfactant properties in solution and micelle formulation. In. Remington's Pharmaceutical Sciences, 18-th Edition, Mack Publishing Company, Easton, Pennsylvania 18042, 1990, pp. 257-309.

    Google Scholar 

  16. G. E. Amidon, W. I. Higuchi, and N. F. H. Ho. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 71:77-84 (1982).

    Google Scholar 

  17. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-421 (1995).

    Google Scholar 

  18. K. Hosoya, K. Kim, and V. H. Lee. Age-dependent expression of p-glycoprotein gp170 in Caco-2 cell monolayers. Pharm. Res. 13:885-890 (1996).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, L., Bridgers, A., Polli, J. et al. Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1. Pharm Res 16, 1812–1817 (1999). https://doi.org/10.1023/A:1018939006780

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018939006780

Navigation